Literature DB >> 22547332

NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice.

Mohammad Salehi-Sadaghiani1, Mehrak Javadi-Paydar, Mohammad Hadi Gharedaghi, Ali Zandieh, Pouria Heydarpour, Yashar Yousefzadeh-Fard, Ahmad Reza Dehpour.   

Abstract

RATIONALE: Previously, we showed that pioglitazone exerts its antidepressant-like effect through peroxisome proliferator-activated receptor gamma receptors and demonstrated the possible involvement of calcium-dependent nitric oxide synthase inhibitors. Based upon the in vitro results, pioglitazone reduces N-methyl-D-aspartate (NMDA)-mediated calcium currents in hippocampal neurons.
OBJECTIVE: In this study, we evaluated the involvement of the NMDA receptor (NMDAR) on the antidepressant-like effect of pioglitazone in the forced swimming test (FST) in mice.
METHOD: After the assessment of locomotor activity in the open-field test, mice were forced to swim individually and the immobility time of the last 4 min was evaluated. Pioglitazone was administered orally with doses of 5, 10, and 20 mg/kg 4 h before FST. To assess the involvement of NMDARs in the possible antidepressant-like effect of pioglitazone, a selective glutamate receptor agonist, NMDA (75 mg/kg, intraperitoneally [i.p.] or 20 ng/mouse, intracerebroventricularly [i.c.v.]), was administered before pioglitazone (20 mg/kg). To further determine a possible role of NMDARs in this effect, a noncompetitive antagonist of the NMDA, MK-801 (0.05 mg/kg, i.p. or 100 ng/mouse, i.c.v.), was coadministered with pioglitazone (10 mg/kg) 4 h prior to FST.
RESULTS: Pioglitazone (20 mg/kg) administered 4 h prior to FST significantly reduced the immobility time. Coadministration of the noneffective doses of pioglitazone and MK-801 revealed an antidepressant-like effect in FST. Moreover, NMDA significantly reversed the antidepressant-like effect of pioglitazone administered 4 h prior to FST.
CONCLUSION: The antidepressant-like effect of pioglitazone in the FST is mediated partly through NMDAR signaling. This study provides a new approach for the treatment of depression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22547332     DOI: 10.1007/s00213-012-2722-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  66 in total

1.  Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test.

Authors:  Fernando T Consoni; Maria A B F Vital; Roberto Andreatini
Journal:  Eur Neuropsychopharmacol       Date:  2006-02-24       Impact factor: 4.600

2.  Association of depression and diabetes complications: a meta-analysis.

Authors:  M de Groot; R Anderson; K E Freedland; R E Clouse; P J Lustman
Journal:  Psychosom Med       Date:  2001 Jul-Aug       Impact factor: 4.312

Review 3.  Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-10

4.  The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice.

Authors:  Burkhard Schütz; Jens Reimann; Lucia Dumitrescu-Ozimek; Karin Kappes-Horn; Gary E Landreth; Britta Schürmann; Andreas Zimmer; Michael T Heneka
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

Review 5.  Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease.

Authors:  Fabrizio Gardoni; Veronica Ghiglieri; Monica Di Luca; Paolo Calabresi
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

6.  NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice.

Authors:  Ewa Poleszak; Piotr Wlaź; Ewa Kedzierska; Dorota Nieoczym; Andrzej Wróbel; Sylwia Fidecka; Andrzej Pilc; Gabriel Nowak
Journal:  Pharmacol Biochem Behav       Date:  2007-08-10       Impact factor: 3.533

7.  Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice.

Authors:  Angelo O Rosa; Manuella P Kaster; Ricardo W Binfaré; Susana Morales; Ester Martín-Aparicio; Maria Luisa Navarro-Rico; Ana Martinez; Miguel Medina; Antonio G García; Manuela G López; Ana Lúcia S Rodrigues
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-06-25       Impact factor: 5.067

8.  Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats.

Authors:  Mohammad Allahtavakoli; Alireza Shabanzadeh; Ali Roohbakhsh; Aliasghar Pourshanazari
Journal:  Basic Clin Pharmacol Toxicol       Date:  2007-11       Impact factor: 4.080

9.  Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells.

Authors:  Paul Aoun; James W Simpkins; Neeraj Agarwal
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-07       Impact factor: 4.799

10.  Evidence for the involvement of the opioid system in the antidepressant-like effect of folic acid in the mouse forced swimming test.

Authors:  Patrícia S Brocardo; Josiane Budni; Kelly R Lobato; Adair Roberto S Santos; Ana Lúcia S Rodrigues
Journal:  Behav Brain Res       Date:  2009-01-08       Impact factor: 3.332

View more
  16 in total

1.  Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests.

Authors:  Arya Haj-Mirzaian; Nastaran Kordjazy; Arvin Haj-Mirzaian; Sattar Ostadhadi; Mehdi Ghasemi; Shayan Amiri; Mehrdad Faizi; AhmadReza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2015-07-15       Impact factor: 4.530

2.  Pioglitazone is an effective treatment for patients with post-stroke depression combined with type 2 diabetes mellitus.

Authors:  Yaozhi Hu; Haiyan Xing; Xiaomeng Dong; Wenxian Lu; Xinxing Xiao; Lilin Gao; Minghu Cui; Jinbo Chen
Journal:  Exp Ther Med       Date:  2015-06-24       Impact factor: 2.447

3.  Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents.

Authors:  Giordano de Guglielmo; Marsida Kallupi; Giulia Scuppa; Gregory Demopulos; George Gaitanaris; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2016-10-06       Impact factor: 4.530

Review 4.  Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder.

Authors:  Reza Rahimian; Claudia Belliveau; Rebecca Chen; Naguib Mechawar
Journal:  Front Psychiatry       Date:  2022-06-16       Impact factor: 5.435

5.  Pioglitazone ameliorates renal ischemia reperfusion injury through NMDA receptor antagonism in rats.

Authors:  Amrit Pal Singh; Nirmal Singh; Preet Mohinder Singh Bedi
Journal:  Mol Cell Biochem       Date:  2016-05-20       Impact factor: 3.396

6.  PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption.

Authors:  Laura B Ferguson; Dana Most; Yuri A Blednov; R Adron Harris
Journal:  Neuropharmacology       Date:  2014-07-15       Impact factor: 5.250

7.  Pioglitazone prevents morphine antinociception tolerance and withdrawal symptoms in rats.

Authors:  Hamed Ghavimi; Kambiz Hassanzadeh; Nasrin Maleki-Dizaji; Alireza Azarfardian; Saeed Ghasami; Elmira Zolali; Mohammad Charkhpour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-06-05       Impact factor: 3.000

8.  Dicholine succinate, the neuronal insulin sensitizer, normalizes behavior, REM sleep, hippocampal pGSK3 beta and mRNAs of NMDA receptor subunits in mouse models of depression.

Authors:  Brandon H Cline; Joao P Costa-Nunes; Raymond Cespuglio; Natalyia Markova; Ana I Santos; Yury V Bukhman; Aslan Kubatiev; Harry W M Steinbusch; Klaus-Peter Lesch; Tatyana Strekalova
Journal:  Front Behav Neurosci       Date:  2015-02-26       Impact factor: 3.558

9.  A Possible Role for Pioglitazone in the Management of Depressive Symptoms in Metabolic Syndrome Patients (EPICAMP Study): A Double Blind, Randomized Clinical Trial.

Authors:  Hamidreza Roohafza; Pedram Shokouh; Masoumeh Sadeghi; Zahra Alikhassy; Nizal Sarrafzadegan
Journal:  Int Sch Res Notices       Date:  2014-08-25

10.  Activation of PPARγ Ameliorates Spatial Cognitive Deficits through Restoring Expression of AMPA Receptors in Seipin Knock-Out Mice.

Authors:  Libin Zhou; Tingting Chen; Guoxi Li; Chaoming Wu; Conghui Wang; Lin Li; Sha Sha; Lei Chen; George Liu; Ling Chen
Journal:  J Neurosci       Date:  2016-01-27       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.